{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:21:31Z","timestamp":1784308891455,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1196492"],"award-info":[{"award-number":["APP1196492"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s12072-023-10530-z","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T19:46:19Z","timestamp":1682019979000},"page":"546-549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN)"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-5476","authenticated-orcid":false,"given":"Jacob","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Gao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ji-Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Omata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"6","key":"10530_CR1","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Mohammed Eslam","year":"2020","unstructured":"Mohammed Eslam M, Sarin SK, Wong VWS, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889\u2013919","journal-title":"Hepatol Int"},{"issue":"7","key":"10530_CR2","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. On behalf of an international consensus panel MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999\u20132014","journal-title":"Gastroenterology"},{"issue":"1","key":"10530_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"3","key":"10530_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cgh.2021.02.030","volume":"20","author":"J Liu","year":"2022","unstructured":"Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese a adults. Clin Gastroenterol Hepatol. 2022;20(3):573\u2013582","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10530_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:739\u2013752","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10530_CR6","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41575-022-00635-5","volume":"19","author":"M Eslam","year":"2022","unstructured":"Eslam M, El-Serag HB, Francque S, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638\u2013651","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10530_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s12072-022-10362-3","volume":"16","author":"Y-C Zhang","year":"2022","unstructured":"Zhang Y-C, Lyu Z-Y, Ma B, et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hepatol Int. 2022;16(4):835\u2013845","journal-title":"Hepatol Int"},{"issue":"5","key":"10530_CR8","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/gutjnl-2021-325102","volume":"71","author":"H Park","year":"2022","unstructured":"Park H, Yoon EL, Cho S, et al. Diabetes is the strongest risk factor of hepatic fibrosis in lea patients with non-alcoholic fatty liver disease. Gut. 2022;71(5):1035\u20131036","journal-title":"Gut"},{"issue":"10","key":"10530_CR9","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1038\/s41591-022-02016-6","volume":"28","author":"AS Meijnikman","year":"2022","unstructured":"Meijnikman AS, Davids M, Hilde Herrema H, et al. Microbiome-derived ethanol in nonalcoholic fatty liver disease. Nat Med. 2022;28(10):2100\u20132106","journal-title":"Nat Med"},{"issue":"6","key":"10530_CR10","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.jhep.2020.07.008","volume":"73","author":"L-Y Mak","year":"2020","unstructured":"Mak L-Y, Yeun M-F, Seto W-K. Letter regarding \u201cA new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.\u201d J Hepatol. 2020;73(6):1573\u20131574","journal-title":"J Hepatol"},{"issue":"1","key":"10530_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/1751-2980.13071","volume":"23","author":"A Al-Omary","year":"2022","unstructured":"Al-Omary A, Byth K, Weltman M, et al. The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C. J Dig Dis. 2022;23(1):33\u201343","journal-title":"J Dig Dis"},{"issue":"1","key":"10530_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S2468-1253(20)30213-2","volume":"6","author":"G Shiha","year":"2021","unstructured":"Shiha G, Alswat K, Al Khatry M, et al. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol. 2021;6(1):57\u201364","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10530_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2468-1253(20)30340-X","volume":"6","author":"N Mendez-Sanchez","year":"2021","unstructured":"Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6(1):65\u201372","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10530_CR14","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","volume":"75","author":"Y Nan","year":"2021","unstructured":"Nan Y, An J, Bao J, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75(2):454\u2013461","journal-title":"J Hepatol"},{"issue":"5","key":"10530_CR15","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1016\/j.jhep.2021.01.015","volume":"74","author":"W Spearman","year":"2021","unstructured":"Spearman W, Desalegn H, Ocama P, et al. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. J Hepatol. 2021;74(5):1256\u20131258","journal-title":"J Hepatol"},{"issue":"10","key":"10530_CR16","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee Y-H, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138-2147.e10","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10530_CR17","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1097\/CM9.0000000000001513","volume":"134","author":"H-J Zhang","year":"2021","unstructured":"Zhang H-J, Wang Y-Y, Chen C, et al. Cardiovascular and renal burdens of metabolic associated fatty liver disease from serial US national surveys, 1999\u20132016. Chin Med J (Engl). 2021;134(13):1593\u20131601","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"10530_CR18","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/jdi.13678","volume":"13","author":"Y Hashimoto","year":"2022","unstructured":"Hashimoto Y, Hamaguchi M, Okamura T, et al. Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. J Diabetes Investig. 2022;13(2):308\u2013316","journal-title":"J Diabetes Investig"},{"issue":"1","key":"10530_CR19","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000435","volume":"13","author":"H Lee","year":"2022","unstructured":"Lee H, Lee HW, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease increases colon cancer risk: a nationwide cohort study. Clin Transl Gastroenterol. 2022;13(1): e00435","journal-title":"Clin Transl Gastroenterol"},{"issue":"10","key":"10530_CR20","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, et al. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172-2181.e6","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10530_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.hbpd.2022.01.006","volume":"21","author":"J Zeng","year":"2022","unstructured":"Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: a community-based study. Hepatobiliary Pancreat Dis Int. 2022;21(2):154\u2013161","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"6","key":"10530_CR22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284\u20131291","journal-title":"J Hepatol"},{"issue":"10","key":"10530_CR23","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S2468-1253(21)00183-7","volume":"6","author":"M Eslam","year":"2021","unstructured":"Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021;6(10):864\u2013873","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10530_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1053\/jhep.2002.30692","volume":"35","author":"S Chitturi","year":"2002","unstructured":"Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35(2):373\u2013379","journal-title":"Hepatology"},{"issue":"6","key":"10530_CR25","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jhep.2022.03.026","volume":"76","author":"QM Anstee","year":"2022","unstructured":"Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: past, present and future. J Hepatol. 2022;76(6):1362\u20131378","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10530-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10530-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10530-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T07:18:30Z","timestamp":1685171910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10530-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10530"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10530-z","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"12 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jacob George, George Lau, Takumi Kawaguchi, Jian Gao Fan, Jia Ji Dong, Fu\u2011Sheng Wang, Manoj Kumar, Shiv Kumar Sarin, Masao Omata, Vincent Wai\u2011Sun Wong, Mohammed Eslam have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}